Ranitidine in the prevention of gastric and duodenal ulcer relapse.
Ranitidine in the prevention of gastric and duodenal ulcer relapse.
复制标题
雷尼替丁预防胃和十二指肠溃疡复发。
作者：
E. Alstead;F. P. Ryan;C. Holdsworth;M. Ashton;M. Moore
对68例胃溃疡或十二指肠溃疡在雷尼替丁150 mg每日2次或安慰剂治疗后已愈合的患者进行了为期一年的雷尼替丁夜间或安慰剂预防性维持治疗。在症状复发时和年底进行胃镜检查。在十二指肠溃疡组中，雷尼替丁组20人中有7人复发，而安慰剂组17人中有15人复发（p <0.001）。在胃溃疡组中，雷尼替丁组15例患者中有1例复发，安慰剂组16例患者中有11例复发（p <0.005）。在试验期间，雷尼替丁没有不良反应。因此，低剂量雷尼替丁维持治疗在预防十二指肠溃疡复发方面是合理有效的，并且似乎在预防胃溃疡复发至少一年方面特别有效。由于胃溃疡更常发生在老年患者中，这些患者通常有手术的医学禁忌症，因此维持治疗可能适用于许多此类患者。
Prophylactic maintenance therapy for one year using ranitidine 150 mg at night or a placebo was assessed in 68 patients whose gastric or duodenal ulcers had previously healed after therapy with ranitidine 150 mg twice daily or placebo. Gastroscopy was carried out on symptomatic relapse and at the end of the year. Of the duodenal ulcer group, seven out of 20 relapsed on ranitidine compared with 15 out of 17 on placebo (p less than 0.001). Of the gastric ulcer group one of 15 patients relapsed on ranitidine compared with 11 of 16 patients on placebo (p less than 0.005). There were no adverse effects from ranitidine during the trial period. Ranitidine in low dose maintenance therapy is therefore reasonably effective in the prevention of relapse of duodenal ulcers and appears to be particularly effective in preventing relapse of gastric ulcers at least for one year. As gastric ulcers occur more frequently in the older patients in whom there are often medical contraindications to surgery, maintenance treatment may be appropriate for many such patients.